Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haitrombopag ethanolamine
- Development stage
- Phase 1
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Haitrombopag ethanolamine is a small-molecule, non-peptide thrombopoietin receptor (TPO-R) agonist developed by Jiangsu Hengrui Pharmaceuticals. It acts as an allosteric agonist by binding to the transmembrane domain of the TPO receptor (also known as MPL), which triggers intracellular signaling pathways, including the JAK/STAT and MAPK pathways. This stimulation promotes the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, leading to increased platelet production. Haitrombopag was approved by the China National Medical Products Administration (NMPA) in 2021 for the treatment of chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to other treatments, and it is also indicated for severe aplastic anemia (SAA).
- Brand names
- Hengqu
- Other names
- haitrombopaghaitrombopag olamine
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)MAPK3 (Mitogen-activated protein kinase 1)JAK2 (Janus kinase 2)TPOR (Thrombopoietin receptor)PNPO (Pyridoxine 5'-phosphate oxidase)STAT3 (Signal Transducer and Activator of Transcription 3)STAT5A (STAT5)
Beyond the preview
Go deeper on haitrombopag ethanolamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haitrombopag ethanolamine.